Four Champaign Co. restaurants receive yellow alerts in health inspections
CHAMPAIGN COUNTY, Ill. (WCIA) — In the latest round of health inspections, four Champaign County restaurants received less than satisfactory results.
On March 27, Tenkyu, located at 301 N Neil St. in Champaign, received a yellow food safety alert after a routine health inspection. The inspector found seven risk factor/intervention violations, two of which were repeated violations.
Federal government tariffs may increase car prices
This included a container of raw squid that was stored above several containers of ready-to-eat sauces in the make table reach-in coolers near the fryers. Another violation was three containers of raw beef and two containers of raw chicken that were stored above containers of cooked rice, cooked chicken, sauce, soup and containers of tofu in the walk-in cooler.
This is the third consecutive inspection that cross-contamination violations have been documented, which resulted in a yellow food safety alert being posted.
Another violation that was repeated for a third time was a consumer advisory-disclosure and reminder violation. In this inspection, an asterisk was not provided for the tuna in the 'Tenkyu Roll,' for the tuna in the 'In N Out Roll,' for the tuna, salmon and flying fish roe in the 'Tuna sandwich,' or for the specific animal derived foods in the 'Sushi' section of the menu.
Other notable violations include a container of cigarettes that was stored next to clean utensils and several packages of raw beef and quail that were 50°F to 54°F and not submerged under cold running water or kept below 41°F during the thawing process. A follow-up inspection will take place in 5-7 business days from that date to ensure corrections have been made.
ET's Downtown Rantoul, located at 107 E Sangamon Ave. in Rantoul, received a yellow food safety alert on March 28. A health inspector found a total of six risk factor/intervention violations, two of which were repeated violations.
Tolono could have first African American Village President
A cold holding 41°F or less violation was found for the fourth consecutive time during a routine checkup, resulting in a yellow food safety alert being posted and a compliance meeting being scheduled. During the latest inspection, the following were above 41°F in the top portion of the make table cooler:
Three containers of cut lettuce (45.3°F, 53.2°F, 51.1°F)
One container of pico de gallo (46.9°F)
Two containers of cut tomatoes (45.5°F and 48°F)
One container of shredded cheese (45°F to 48°F)
One container of coleslaw (46.8°F)
One container of cut spinach (52.9°F)
There were six separate violations found under this category alone, including a number of foods that were over the necessary cooling temperatures.
The other repeat violation that was found was a cooling-cooked time/temperature control for safety foods violation, which was observed for the second consecutive routine inspection. In this inspection, cooked chicken wings (prepared the day before) were 44.1°F in the walk-in cooler. According to an employee, the chicken wings had remained in the cooler since the previous day.
The compliance meeting was scheduled for April 2 at 10:30 a.m. A number of discussion notes were also posted at the bottom of the report.
On March 31, H Mart, located at 220 N Broadway Ave in Urbana, received a yellow food safety alert. While no risk factor/intervention violations were found in the inspection, a violation correction form (VCF) was not completed by its due date.
Champaign Police increasing patrol to combat distracted drivers
This form was issued during the routine inspection on Feb. 28 in response to a food package labeling violation for several facility-packaged food items that were not labeled with the major allergens they contained. Adequate food labels for the facility-packaged foods were not received by the VCF extended due date of March 28 at 4 p.m.
As a result, a yellow food safety alert was posted. In addition, if adequate food labels for facility-packaged foods are not received by 4 p.m. on April 11, the health permit will be suspended, and H Mart will receive a red 'Closed' placard.
Urbana Country Club, located at 100 E Country Club Road in Urbana, received a yellow food safety alert on April 1. Four risk factor/intervention violations were found, one of which was a repeat violation during the inspection.
A cold holding 41°F or less violation was found during the third consecutive routine inspection, which resulted in the yellow food safety alert being issued. In this particular inspection, the following items were found inside in the 'Turbo-air' make-table cooler on the left side of the pizza oven: Hard-boiled eggs (48.2°F) inside the top part, chicken salad (46.2°F) and cut melons (44.6°F) inside the reach-in part.
Police respond to car versus bicyclist accident in Champaign
Additionally, the following items were found inside the pull-out coolers opposite the grill on the cookline:
Chili (46°F)
Pulled short ribs (62.4°F)
Corned beef (48.5°F)
Diced ham (46.2°F)
Cooked pasta (43.8°F)
Mushroom cream sauce (46.7°F)
Shredded cheddar cheese (46.5°F)
An employee said that the chili was thawed under cold running water for 45 minutes and was added to the pull-out cooler approximately 2.5 hours before, the short rib was pulled, portioned and added to the pull-out cooler approximately 2.5 hours prior, corned beef was portioned and added to the pull-out cooler approximately 3 hours prior, ham, pasta and mushroom cream sauce were moved from the walk-in cooler to the pull-out cooler approximately 4 hours prior and the cheese was sitting in the cooler since the week before.
As a result of the repeated violation, a Repeat P & Pf Root Cause Questionnaire was scheduled for April 2 at 9 a.m. and a follow-up inspection will be conducted to verify the long-term violation correction in 5-7 business days after the questionnaire is completed. Adequate checklists for the cold holding violation must be sent to the Champaign County Health Department by 8 a.m. on April 8.
For more information on other recent restaurant inspections, visit the Champaign-Urbana Public Health District's website.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 hours ago
- Yahoo
'1000-Lb. Roomies'' Jaz in Tears After Doc Says She ‘Won't Survive' Without Losing Weight: ‘I Feel Like I Can't Do It' (Exclusive)
In PEOPLE's exclusive clip of 1000-Lb. Roomies, Jaz learns she has to lose 130 lbs. to qualify for bariatric surgery Her doctor tells her that if she doesn't commit to losing weight she 'won't survive long' Nesha tells Jaz that they can work on their weight-loss journeys together, vowing to give her friend 'full support'Jasmine 'Jaz' Wallace is getting a huge wake-up call from her doctor. In PEOPLE's exclusive clip from Tuesday's episode of 1000-Lb. Roomies, the 41-year-old is visiting her doctor, Dr. Sarvenaz Nouri, alongside her best friend Nesha Harris when she weighs in at 630 lbs. Nouri explains that Jaz needs to commit to her weight loss journey so that she can qualify for bariatric surgery. 'Our goal is to help you to get you to surgery,' she says. 'For the surgery I want you to be around 500 lbs. So you do need to lose about 130 lbs before surgery.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Nesha is shocked by the news, noting that 'that's a whole person.' Meanwhile, Jaz isn't feeling confident in her ability to lose the weight on her own. '130 lbs. in order for me to get this surgery, I feel like I can't do it,' Jaz says. 'That's why I'm here.' In the clip, she then asks Nouri if Nesha should join in on this health journey. Nesha reveals that the last time she stepped on a scale, she weighed 425 lbs. However, she's not on board with undergoing bariatric surgery like Jaz. 'It's something that I just never saw myself doing,' Nesha says. 'I don't know, I'm just not for it. But that could be our goal together. If you have to be on a certain diet, I'll be on that diet with you. I got you.' is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more! ! Nouri then asks Jaz how she's feeling about her weight-loss goal. She admits that she's nervous. 'If you don't lose weight and if you don't get the weight loss surgery to lose weight, you will not survive for that long,' Nouri warns. 'Hearing that Jaz doesn't have long to live is scary,' Nesha says. 'I feel like once you hear it from a doctor, it really kind of just makes it that much more real. It hits you. It just hits you like a ton of bricks.' 'And whatever she has to do, I'm in full support,' she adds. Nouri tells Jaz she believes she can do it. However, Jaz lets out a big sigh in the doctor's office and then shares that she's worried about not being there one day for her loved ones, including her 10-year-old daughter. 'I'm very scared,' Jaz says, breaking down in tears. 'How many days I got left? How many days I got left to be a parent? How many days I got left to be an auntie, a sister, a daughter and a best friend?' A new episode of 1000-Lb. Roomies airs Tuesday, June 10 at 10PM ET/PT. Read the original article on People


Miami Herald
a day ago
- Miami Herald
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline 83% of subjects maintained a clinically meaningful benefit with a 3 or more point improvement in Revised Venous Clinical Severity Score (rVCSS) 9.1 point average rVCSS improvement among the clinically meaningful benefit cohort Subjects experienced a median 74% improvement in leg pain Interim follow-up data indicate sustained improvements across all venous-specific quality-of-life (QoL) indicators A decision from the U.S. Food and Drug Administration (FDA) on the VenoValve is anticipated in the second half of 2025 Company to host live webcast with presenting Principal Investigator, today, June 6th at 11:20 AM ET / 10:20 AM CT - Access the Webcast Here IRVINE, CA / ACCESS Newswire / June 6, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that interim two-year follow-up data on 42 subjects from the 75 person VenoValve U.S. pivotal trial will be presented today by lead enroller Dr. Cassius Iyad Ochoa Chaar, at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting (VAM25) being held June 4-7, 2025 in New Orleans, LA. Additionally, the Company announced it will host a live webcast to discuss these interim results today, Friday, June 6th at 11:20 AM ET / 10:20 AM CT (details below). Key interim two-year follow-up data being presented at VAM25 include: 83.3% of subjects (n=35/42) maintained a clinically meaningful benefit, defined as an improvement of 3 or more points in the revised Venous Clinical Severity Score (rVCSS).9.1 point average rVCSS improvement among the responder cohort.A median 74% improvement in leg pain, as measured by the Visual Analog Scale (VAS).Wound healing outcomes in 17 subjects with 25 ulcers showed that 60% of ulcers healed completely, 24% decreased in size, and 16% increased in outcomes also demonstrated sustained improvements across all venous specific QoL indicators (VEINES-QoL/Sym).Among the subjects (n=30), a 100% valve patency rate. All values were calculated comparing each patient's baseline levels to the reported values at the patient's 24-month visit. The Revised Venous Clinical Severity Score (rVCSS) is a clinically validated scoring system used to track the progression or regression of venous diseases. "These interim two-year follow-up data demonstrate substantial and sustained improvement across all effectiveness endpoints at two years. This is extremely encouraging, especially when you consider that all the patients enrolled in the study had severe CVI and failed all other treatment options," said Robert Berman, enVVeno Medical's Chief Executive Officer. "Despite attempts over many decades, nobody has been able to create an effective treatment for severe CVI caused by malfunctioning valves in the deep veins of the leg. The VenoValve has the potential to change the treatment paradigm for deep venous CVI, both for the millions of patients suffering from severe CVI and the thousands of vascular surgeons who have been waiting for an effective treatment option." Dr. Cassius Iyad Ochoa Chaar, who is the Associate Professor of Surgery, Division of Vascular Surgery and Endovascular Therapy, Yale School of Medicine, will present the abstract titled, "Patients with Deep Venous Reflux Continue to Experience Clinical Improvement 2-year after Implantation of the VenoValve" today at VAM 2025. The VenoValve is a potential first-in-class, surgical replacement venous valve for patients with severe deep venous CVI. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA), with a decision anticipated in the second half of 2025. Webcast Details The Company will host a webcast presentation to discuss the results for investors, analysts and other interested parties today, June 6, 2025, at 11:20 AM ET / 10:20 AM CT. Joining enVVeno management for the event will be Dr. Chaar. The live webcast will be accessible on the Events page of the enVVeno website, and will be archived for 90 days. About CVI Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of $4 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. Cautionary Note on Forward-Looking Statements This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. INVESTOR CONTACT:Jenene Thomas, JTC Team, LLCNVNO@ 824-0775 MEDIA CONTACT:Glenn Silver, FINN 818-8198 SOURCE: enVVeno Medical Corporation
Yahoo
4 days ago
- Yahoo
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline 83% of subjects maintained a clinically meaningful benefit with a 3 or more point improvement in Revised Venous Clinical Severity Score (rVCSS) 9.1 point average rVCSS improvement among the clinically meaningful benefit cohort Subjects experienced a median 74% improvement in leg pain Interim follow-up data indicate sustained improvements across all venous-specific quality-of-life (QoL) indicators A decision from the U.S. Food and Drug Administration (FDA) on the VenoValve is anticipated in the second half of 2025 Company to host live webcast with presenting Principal Investigator, today, June 6th at 11:20 AM ET / 10:20 AM CT - Access the Webcast Here IRVINE, CA / / June 6, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that interim two-year follow-up data on 42 subjects from the 75 person VenoValve U.S. pivotal trial will be presented today by lead enroller Dr. Cassius Iyad Ochoa Chaar, at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting (VAM25) being held June 4-7, 2025 in New Orleans, LA. Additionally, the Company announced it will host a live webcast to discuss these interim results today, Friday, June 6th at 11:20 AM ET / 10:20 AM CT (details below). Key interim two-year follow-up data being presented at VAM25 include: 83.3% of subjects (n=35/42) maintained a clinically meaningful benefit, defined as an improvement of 3 or more points in the revised Venous Clinical Severity Score (rVCSS). 9.1 point average rVCSS improvement among the responder cohort. A median 74% improvement in leg pain, as measured by the Visual Analog Scale (VAS). Wound healing outcomes in 17 subjects with 25 ulcers showed that 60% of ulcers healed completely, 24% decreased in size, and 16% increased in size. Patient-reported outcomes also demonstrated sustained improvements across all venous specific QoL indicators (VEINES-QoL/Sym). Among the subjects (n=30), a 100% valve patency rate. All values were calculated comparing each patient's baseline levels to the reported values at the patient's 24-month visit. The Revised Venous Clinical Severity Score (rVCSS) is a clinically validated scoring system used to track the progression or regression of venous diseases. "These interim two-year follow-up data demonstrate substantial and sustained improvement across all effectiveness endpoints at two years. This is extremely encouraging, especially when you consider that all the patients enrolled in the study had severe CVI and failed all other treatment options," said Robert Berman, enVVeno Medical's Chief Executive Officer. "Despite attempts over many decades, nobody has been able to create an effective treatment for severe CVI caused by malfunctioning valves in the deep veins of the leg. The VenoValve has the potential to change the treatment paradigm for deep venous CVI, both for the millions of patients suffering from severe CVI and the thousands of vascular surgeons who have been waiting for an effective treatment option." Dr. Cassius Iyad Ochoa Chaar, who is the Associate Professor of Surgery, Division of Vascular Surgery and Endovascular Therapy, Yale School of Medicine, will present the abstract titled, "Patients with Deep Venous Reflux Continue to Experience Clinical Improvement 2-year after Implantation of the VenoValve" today at VAM 2025. The VenoValve is a potential first-in-class, surgical replacement venous valve for patients with severe deep venous CVI. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA), with a decision anticipated in the second half of 2025. Webcast Details The Company will host a webcast presentation to discuss the results for investors, analysts and other interested parties today, June 6, 2025, at 11:20 AM ET / 10:20 AM CT. Joining enVVeno management for the event will be Dr. Chaar. The live webcast will be accessible on the Events page of the enVVeno website, and will be archived for 90 days. About CVI Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of $4 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. Cautionary Note on Forward-Looking Statements This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. INVESTOR CONTACT:Jenene Thomas, JTC Team, LLCNVNO@ 824-0775 MEDIA CONTACT:Glenn Silver, FINN 818-8198 SOURCE: enVVeno Medical Corporation View the original press release on ACCESS Newswire